0
0.5
1
1.5
2+
Mortality
93%
Improvement
Relative Risk
Death/hospitalization
56%
primary
Hospitalization
48%
Hospitalization/ER
40%
SQ vs. IV death
53%
SQ vs. IV death/hosp.
-71%
SQ vs. IV hospitalization
-79%
SQ vs. IV ER/hosp.
15%
Casirivimab/i.. McCreary et al. LATE TREATMENT
Is late treatment with casirivimab/imdevimab beneficial for COVID-19?
Prospective study of 2,185 patients in the USA (Jul - Oct 2021)
Lower mortality (p=0.009) and death/hosp. (p=0.00031)
c19early.org
McCreary et al., medRxiv, December 2021
Favors casirivimab/im..
Favors control